{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:19Z","timestamp":1791231439674,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Derivative chromosome 9 deletions are seen in 10% to 15% of patients with chronic myelogenous leukemia and have been associated with a poor prognosis; however, no studies have been performed in the context of a randomized clinical trial. We developed a DNA-based deletion screen and investigated 339 chronic phase patients treated with interferon-\u03b1 as first-line therapy in 3 controlled German studies with a median observation time of 7 years. Deletions were detected in pretreatment DNA of 59 of 339 (17%) patients. Of these, 21 spanned the ABL\/BCR junction and 38 were centromeric (n = 20) or telomeric (n = 18) of the breakpoint. There was no significant difference in overall survival between deleted and nondeleted patients. Patients with breakpoint-spanning deletions had poorer survival compared with patients without deletions (4.7 versus 7.8 years; P = .003), but this was not significant when censored at allogeneic stem cell transplantation (n = 129) or imatinib (n = 62) treatment in the first chronic phase (P = .078). Unexpectedly, deletions that did not span the breakpoint were associated with improved survival compared with cases without deletions (P = .001). Multiple Cox regression analysis indicated that deletion status (P = .007), age (P = .018), and spleen enlargement (P &lt; .001) were significant independent indicators of survival and confirmed that only deletions spanning the ABL\/BCR breakpoint were associated with an adverse prognosis (P = .039).<\/jats:p>","DOI":"10.1182\/blood-2007-02-074252","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T02:23:04Z","timestamp":1177467784000},"page":"1283-1290","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia"],"prefix":"10.1182","volume":"110","author":[{"given":"Sebastian","family":"Kreil","sequence":"first","affiliation":[{"name":"Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom;"},{"name":"III Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany;"},{"name":"Gesellschaft f\u00fcr Informationsverarbeitung und Statistik in der Medizin e.V., Munich, Germany and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL (M\u00fcnchner Leuk\u00e4mielabor), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Waghorn","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chase","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"III Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"III Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713141600000_B1","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood.V98.9.2879","article-title":"ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.","volume":"98","author":"de la Fuente","year":"2001","journal-title":"Blood"},{"key":"2019111713141600000_B2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.","volume":"81","author":"Melo","year":"1993","journal-title":"Blood"},{"key":"2019111713141600000_B3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/10428190310001623900","article-title":"Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes.","volume":"45","author":"Specchia","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2019111713141600000_B4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"key":"2019111713141600000_B5","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"2019111713141600000_B6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/gcc.10197","article-title":"A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.","volume":"37","author":"Lee","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111713141600000_B7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/gcc.10116","article-title":"Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients.","volume":"35","author":"Storlazzi","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111713141600000_B8","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.V97.11.3581","article-title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis.","volume":"97","author":"Kolomietz","year":"2001","journal-title":"Blood"},{"key":"2019111713141600000_B9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.leu.2402969","article-title":"Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome.","volume":"17","author":"Kolomietz","year":"2003","journal-title":"Leukemia"},{"key":"2019111713141600000_B10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0165-4608(01)00412-5","article-title":"Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis.","volume":"128","author":"Cohen","year":"2001","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"2019111713141600000_B11","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"2019111713141600000_B12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","article-title":"Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.","volume":"17","author":"Hehlmann","year":"2003","journal-title":"Leukemia"},{"key":"2019111713141600000_B13","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"2019111713141600000_B14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2019111713141600000_B15","first-page":"205","article-title":"Prognostic factors.","volume-title":"Chronic Myeloid Leukemia\u2014Biology and Treatment","author":"Hasford","year":"2001"},{"key":"2019111713141600000_B16","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1093\/nar\/gnf056","article-title":"Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.","volume":"30","author":"Schouten","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2019111713141600000_B17","unstructured":"National Center for Biotechnology Information\n          BLAST: Basic Local Alignment Search Tool\n          Accessed November 2004\n          \n            www.ncbi.nlm.nih.gov\/blast\/"},{"key":"2019111713141600000_B18","unstructured":"National Center for Biotechnology Information\n          Accessed November 2004\n          \n            www.ncbi.nlm.nih.gov"},{"key":"2019111713141600000_B19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.1997.32645.x","article-title":"Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group.","volume":"97","author":"Reiter","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111713141600000_B20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjc.6602121","article-title":"Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.","volume":"91","author":"Bunyan","year":"2004","journal-title":"Br J Cancer"},{"key":"2019111713141600000_B21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/gcc.10215","article-title":"High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.","volume":"37","author":"Reid","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111713141600000_B22","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V99.12.4547","article-title":"Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.","volume":"99","author":"Huntly","year":"2002","journal-title":"Blood"},{"key":"2019111713141600000_B23","first-page":"3870","article-title":"Frequent deletion of hSNF5\/INI1, a component of the SWI\/SNF complex, in chronic myeloid leukemia.","volume":"59","author":"Grand","year":"1999","journal-title":"Cancer Res"},{"key":"2019111713141600000_B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/gcc.10183","article-title":"Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.","volume":"36","author":"Albano","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111713141600000_B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gcc.20161","article-title":"Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.","volume":"43","author":"Kim","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111713141600000_B26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/humu.20330","article-title":"MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q.","volume":"27","author":"Vorstman","year":"2006","journal-title":"Hum Mutat"},{"key":"2019111713141600000_B27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.2000.02366.x","article-title":"Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.","volume":"111","author":"Bonifazi","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111713141600000_B28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2141.2001.02873.x","article-title":"Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon: comments.","volume":"114","author":"Pfirrmann","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111713141600000_B29","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"2019111713141600000_B30","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2003-10-3605","article-title":"Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.","volume":"103","author":"Kluin-Nelemans","year":"2004","journal-title":"Blood"},{"key":"2019111713141600000_B31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood.V68.5.1123.1123","article-title":"Frequent and extensive deletion during the 9,22 translocation in CML.","volume":"68","author":"Popenoe","year":"1986","journal-title":"Blood"},{"key":"2019111713141600000_B32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0609.2004.00356.x","article-title":"Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia.","volume":"74","author":"Yoong","year":"2005","journal-title":"European Journal of Haematology"},{"key":"2019111713141600000_B33","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"2019111713141600000_B34","first-page":"49","article-title":"Establishment of a lymphoblastoid cell line, SD-1, expressing the p190 bcr-abl chimaeric protein.","volume":"5","author":"Dhut","year":"1991","journal-title":"Leukemia"},{"key":"2019111713141600000_B35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1996.00350.x","article-title":"Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.","volume":"92","author":"Melo","year":"1996","journal-title":"Br J Haematol"},{"key":"2019111713141600000_B36","first-page":"952","article-title":"Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.","volume":"91","author":"Fourouclas","year":"2006","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1283\/1479424\/zh801607001283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1283\/1479424\/zh801607001283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T18:14:30Z","timestamp":1574014470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/4\/1283\/23127\/Heterogeneous-prognostic-impact-of-derivative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-02-074252","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}